Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Relative Bioavailability and Tolerability of 160mg Subcutaneous Bimekizumab in Healthy Subjects

NCT05028127 is registered in ClinicalTrials.gov with UCB Celltech as lead sponsor.

NCT NCT05028127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05028127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Relative Bioavailability and Tolerability of 160mg Subcutaneous Bimekizumab in Healthy Subjects
Lead sponsor
UCB Celltech
Phase
Phase 1
Overall status
Completed
Start date
March 4, 2016
Completion date
June 17, 2016
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers